(a) The S-value metrics correlates with the coverage. Following RNA-seq reads mapping on the reference genome (version GRCh37.75) using TopHat, we computed the coverage of each peptide-coding region (PCR). For each identified MAP, we then plotted this coverage metrics as a function of the S-value, both in log 10 . Since the S-value metrics approximates the number of reads spanning the whole PCR while the coverage also takes into account reads spanning PCR by at least one base pair (bp), we reasoned that the coverage would slightly overestimate the S-value. For a few MAPs, the S-value appeared to underestimate the coverage: analysis of those MAPs revealed that most of them derived from genes in the RPS and RPL families. Highly similar in sequence but not identical, these genes will generate many 11-amino acids entries in the all-frames database, having different S-value but all containing the 9-amino acids MAPs of interest. Since we kept only one S-value among all possible ones, the real S-value of this 9-mers was therefore a strong underestimation of the coverage given by TopHat especially since this mapper maps multihit reads. (b) An S-value threshold ≥ 10 yields a database having a size manageable by Mascot search engine. This graph represents the percentage of peptides above the S-value threshold as a function of the S-value threshold. Number of unique sequences in the database as well as its size (in bites) were computed for three S-value thresholds (red dots) as detailed in the table. For comparison, the size of a typical reference protein database, such as UniProt, is about 0.5 x 10 9 bites.
Supplementary Figure 2. MS validation of 18 cryptic MAPs.
Among the 168 cryptic MAPs identified in our study, 18 were randomly selected and subjected to MS validation using synthetic version of them. Fig.  2a . We performed peptide elution on B-LCLs from three other subjects (subjects 2-4) that shared 4, 2 or no HLA allele with subject 1, respectively. Since we only wanted to validate MAPs from subject 1 rather than explore the whole immunopeptidome of subjects 2-4, we constructed a validation database that contained all identifications made in subject 1 concatenated with their reverse sequences. Identifications made in subjects 2-4 using Mascot were compared to the list of conventional and cryptic MAPs from subject 1 allowing us to compute a percentage of MAPs recovery per HLA allele relative to subject 1 for each subject.
